PXD056090
PXD056090 is an original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Protective Effects of FXI Inhibition by Abelacimab in a Baboon Model of live Staphylococcus aureus Sepsis |
| Description | Sepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multi-organ failure, leading to high morbidity and mortality. This study investigates the therapeutic potential of Abelacimab, a novel monoclonal antibody targeting the plasma zymogen coagulation fFactor XI/XIa (FXI/XIa), in a baboon model of live Staphylococcus aureus sepsis. Healthy Papio anubis baboons were randomly assigned to either a control or a treatment group receiving Abelacimab. Both groups (n=6, each) were intravenously infused with a LD50 dose of live S. aureus. The treatment group was administered Abelacimab, 30 minutes after bacterial infusion. Hematologic, coagulation, inflammatory, and organ function parameters were monitored for 7 days or until the animals exhibited signs of irreversible organ failure. Proteomic analysis was conducted to elucidate the underlying mechanisms by which Abelacimab offered protection. All six Abelacimab-treated baboons survived to the 7-day endpoint, while three out of six untreated controls succumbed to sepsis within 102 hours. Abelacimab significantly attenuated sepsis-induced consumptive coagulopathy, as evidenced by coagulation and fibrinolysis markers. Treated animals showed decreased levels of pro-inflammatory cytokines, reduced neutrophil activation, and preservation of endothelial integrity, leading to reduced organ damage. Proteomic analysis revealed that Abelacimab modulated pathways related to coagulation, inflammation, and tissue injury, contributing to improved survival outcomes. We found that FXI/XIa inhibition by Abelacimab offers significant protection in a model of live S. aureus sepsis by attenuating activation of coagulation factors, reducing inflammation, and preventing organ failure. These findings suggest that targeting FXI may be a promising therapeutic strategy for managing sepsis, addressing multiple facets of its complex pathophysiology. |
| HostingRepository | MassIVE |
| AnnounceDate | 2025-09-02 |
| AnnouncementXML | Submission_2025-09-02_11:32:14.116.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Non peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Stephanie Byrum |
| SpeciesList | scientific name: Papio anubis; common name: olive baboon; NCBI TaxID: 9555; |
| ModificationList | Oxidation |
| Instrument | Orbitrap Exploris 480 |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
|---|---|---|---|
| 0 | 2024-09-23 06:17:24 | ID requested | |
| ⏵ 1 | 2025-09-02 11:32:14 | announced |
Publication List
| no publication |
Keyword List
| submitter keyword: Abelacimab, sepsis, baboon model, Staphylococcus aureus, organ failure |
Contact List
| Florea Lupu | |
|---|---|
| contact affiliation | Oklahoma Medical Research Foundation |
| contact email | Lupu@omrf.org |
| lab head | |
| Stephanie Byrum | |
| contact affiliation | St Jude Children's Research Hospital |
| contact email | sbyrum@stjude.org |
| dataset submitter | |
Full Dataset Link List
| MassIVE dataset URI |
| Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://massive-ftp.ucsd.edu/v08/MSV000095928/ |
to receive all new ProteomeXchange dataset release announcements!
